Posted by Michael Wonder on 05 Sep 2018
Chi-Med announces the approval of fruquintinib capsules for previously treated colorectal cancer in China
5 September 2018 - The first China-discovered and developed treatment for CRC approved in China.
Hutchison China MediTech today announces that fruquintinib capsules have been granted approval for drug registration by the National Medical Products Administration of China for the treatment of metastatic colorectal cancer patients, who have failed at least two prior systemic anti-neoplastic therapies including fluoropyrimidine, oxaliplatin and irinotecan, with or without prior use of anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor therapies.
Fruquintinib is a highly selective and potent small molecule oral inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 designed to be a global best-in-class VEGFR inhibitor for many types of solid tumours.
Fruquintinib capsules are to be marketed in China under the brand name Elunate. The approval is based on results from the Phase III FRESCO trial, which were presented at the American Society of Clinical Oncology 2017 Meeting and published in the JAMA in 2018.
